European Bioanalysis Forum: recommendation on dealing with hemolyzed and hyperlipidemic matrices

Area of Science:

• Pharmacokinetics and Drug Metabolism
• Analytical Chemistry
• Bioanalytical Science

Background:

• Recent bioanalytical method validation guidelines recommend investigating matrix effects in special matrices.
• These guidelines lack clarity on implementation for matrices like hemolytic and hyperlipidemic plasma.
• The European Bioanalysis Forum (EBF) initiated discussions to address this ambiguity.

Purpose of the Study:

• To provide specific guidance on defining and validating bioanalytical methods for hemolytic and hyperlipidemic plasma.
• To offer strategies for handling study samples with these special matrix characteristics.
• To present EBF recommendations for consistent implementation of matrix effect investigations.

Main Methods:

• In-depth discussion and feedback solicitation from EBF member companies.
• Development of specific criteria for defining hemolytic and hyperlipidemic plasma.
• Formulation of validation strategies tailored to these challenging matrices.

Main Results:

• Established clear definitions for hemolytic and hyperlipidemic plasma.
• Outlined practical approaches for validating bioanalytical methods in these matrices.
• Provided recommendations for managing study samples exhibiting these properties.

Conclusions:

• The manuscript presents actionable recommendations for bioanalytical method validation in special matrices.
• These findings aim to enhance the reliability and consistency of bioanalytical data in drug development.
• The guidance facilitates the implementation of recent regulatory expectations for matrix effect assessment.